Health CarePharmaceuticals and Biotechnology
  • Price (CHF)0.95
  • Today's Change-0.046 / -4.62%
  • Shares traded58.87k
  • 1 Year change-42.25%
  • Beta0.8647
Data delayed at least 15 minutes, as of Jan 14 2022 16:31 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

  • Revenue in CHF (TTM)4.64m
  • Net income in CHF-13.05m
  • Incorporated2007
  • Employees23.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Onxeo SA1.34m-9.10m40.65m29.00--1.15--30.37-0.1104-0.11040.01610.3690.0237--0.191551,320.00-16.11-31.58-19.61-36.6572.4991.48-679.81-473.89---9.200.2335---58.59-12.59103.23---21.92--
genOway SA12.99m-422.77k43.76m121.00--2.6935.673.37-0.0427-0.04271.661.720.4479-0.03092.46105,461.90-1.461.57-1.982.51100.2890.86-3.262.712.03-3.000.40070.0016.486.3333.69--94.79--
Arctic Bioscience AS-10.43bn-10.43bn44.35m---------------------------------------------------31.77---466.19------
Chill Brands Group PLC401.08k-6.00m45.06m2.00------112.36-0.0247-0.02490.0017-0.00110.12580.30050.4079160,435.00-188.20-49.16-490.04-61.84-12.67---1,496.10-474.430.2451------246.49---63.08---71.69--
OptiBiotix Health PLC2.32m25.84m45.62m8.001.981.401.7419.680.210.210.01850.2970.10458.012.21231,808.80116.555.69120.406.0357.0061.061,114.9664.923.72--0.0298--104.50122.08345.09--181.84--
Addex Therapeutics Ltd4.64m-13.05m46.81m23.00--2.43--10.08-0.4017-0.40170.14490.39070.2463--14.11201,902.60-69.23-39.02-81.03-45.52-----281.08-249.48----0.0376--36.8958.1613.00------
Oxford Biodynamics PLC647.48k-6.71m47.16m37.00--3.30--72.84-0.058-0.0580.00560.11390.0347--0.477914,000.00-35.99-19.74-39.37-21.25-----1,035.91-302.727.46-76.560.0433---49.72-8.27-54.04---2.66--
Tissue Regenix Group PLC16.93m-11.29m47.47m78.00--1.42--2.80-0.0012-0.00120.00190.00380.34771.095.23173,602.60-23.23-28.20-24.99-31.1244.8147.90-66.81-100.563.65-6.170.1707---1.5773.50-39.24--14.07--
CoDon AG6.94m-11.95m48.46m120.00--2.81--6.98-0.6301-0.63010.35270.61750.27211.216.1955,458.33-46.82-45.36-54.91-53.2590.9489.62-172.07-140.221.91-11.040.3005---9.094.15-9.82---12.60--
PCI Biotech Holding ASA693.99k-9.37m48.68m15.00--3.43--70.14-2.41-2.410.17823.650.034--0.459443,466.70-45.95-31.76-51.31-35.11-----1,350.06-575.29---8.640.0145---21.55-6.7818.60------
New Nordic Healthbrands AB51.81m2.88m50.81m37.0017.634.0517.120.98094.594.5982.5819.982.284.614.56--12.7113.0324.0527.2817.9517.585.565.251.1287.420.112538.18-0.56328.56-36.729.4118.9043.10
RhoVac AB1.03m-4.97m51.11m----8.11--49.72-2.58-2.580.5333.270.1052--0.8209---50.92-42.16-56.10-46.72-----483.96-950.54---745.970.00--0.558---16.51------
Wockhardt Bio AG301.58m-40.88m52.47m----0.1847--0.174-0.7325-0.73255.815.470.47921.802.50---6.50-1.96-8.19-3.0051.4451.88-13.55-4.233.90-3.450.5092---15.93-8.7151.896.81-17.47--
Pierrel S.p.A.21.72m2.62m52.54m305.0019.053.0012.012.420.01160.01160.09420.07340.50661.3415.35--6.12-2.917.92-6.0069.6066.1312.07-5.461.425.380.5632---16.002.45-15.4253.4026.32--
Shedir Pharma Srl Unipersonale44.98m3.59m52.84m71.0014.722.038.771.170.30090.30093.772.180.90221.396.53545,683.607.26--9.78--57.66--8.04--2.057.880.3601---14.28--38.34------
Data as of Jan 14 2022. Currency figures normalised to Addex Therapeutics Ltd's reporting currency: Swiss Franc CHF

Institutional shareholders

15.18%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 21 Dec 20213.75m7.62%
Caxton Corp.as of 27 Apr 20211.60m3.24%
Credit Suisse Asset Management (Schweiz) AGas of 23 Sep 20211.21m2.46%
Herculis Partners SAas of 31 Dec 2020454.59k0.92%
UBS Asset Management Switzerland AGas of 05 Jan 2022233.25k0.47%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020110.14k0.22%
Pictet Asset Management SAas of 31 Aug 202145.82k0.09%
BlackRock Asset Management Schweiz AGas of 06 Jan 202241.67k0.09%
Sectoral Asset Management, Inc.as of 31 Jul 201820.90k0.04%
Lombard Odier Asset Management (Switzerland) SAas of 30 Sep 202117.69k0.04%
More ▼
Data from 31 Dec 2020 - 31 Dec 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.